OOIR: Observatory of International Research

Papers

(The H4-Index of Biodrugs is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Designer Exosomes: A New Platform for Biotechnology Therapeutics	123
Therapeutic siRNA: State-of-the-Art and Future Perspectives	82
Cell-Free Protein Synthesis: A Promising Option for Future Drug Development	63
Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future	57
Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease	57
Beyond Antibodies: The DARPin® Drug Platform	52
Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy	48
Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks	44
Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic	41
Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins	41
In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies	38
Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges	36
European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption	36
The Importance of Countering Biosimilar Disparagement and Misinformation	33
European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice	32
The Path Towards a Tailored Clinical Biosimilar Development	32
Administration of CD4+CD25highCD127−FoxP3+ Regulatory T Cells for Relapsing-Remitting Multiple Sclerosis: A Phase 1 Study	32
The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma	30
Dengue Vaccines: An Update	29
CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success	29
Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies	29
Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis	28
Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond	28
Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA	26
Safety of Intravitreal Gene Therapy for Treatment of Subjects with Leber Hereditary Optic Neuropathy due to Mutations in the Mitochondrial ND4 Gene: The REVEAL Study	25